Recurrence in resected gastroenteropancreatic neuroendocrine tumors

Simron Singh, David L. Chan, Lesley Moody, Ning Liu, Hadas D. Fischer, Peter C. Austin, Eva Segelov

Research output: Contribution to journalLetterOtherpeer-review

25 Citations (Scopus)


Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities
Original languageEnglish
Pages (from-to)583-585
Number of pages3
JournalJAMA Oncology
Issue number4
Publication statusPublished - 1 Apr 2018


  • Oncology
  • Pancreatic Cancer
  • Gastrointestinal Cancer
  • Pancreatic disease
  • Gastroenterology
  • Gastroenterology and hepatology

Cite this